Provided by Tiger Trade Technology Pte. Ltd.

TRANSCENTA-B

2.390
0.000
Volume:- -
Turnover:- -
Market Cap:1.08B
PE:-3.33
High:2.390
Open:2.390
Low:2.390
Close:2.390
52wk High:5.800
52wk Low:0.900
Shares:450.00M
HK Float Shares:450.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.717
ROE:-34.28%
ROA:-12.81%
PB:1.45
PE(LYR):-3.33
PS:100.71

Loading ...

Transcenta (06628) Announces January 2026 Monthly Return on Movements in Securities

Bulletin Express
·
Feb 05

Transcenta Holding Limited (6628) Reports Progress on Measures Addressing Disclaimer of Opinion

Bulletin Express
·
Jan 22

Transcenta Holding Limited's (HKG:6628) largest shareholders are retail investors who were rewarded as market cap surged HK$130m last week

Simply Wall St.
·
Jan 08

Transcenta Grants Two Million Award Shares

MT Newswires Live
·
Dec 29, 2025

TRANSCENTA-B (06628) Grants 2 Million Shares as Incentive Awards

Stock News
·
Dec 29, 2025

Transcenta Holding Grants 2 Million Award Shares Under Share Incentive Scheme

Reuters
·
Dec 29, 2025

BRIEF-Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.

Reuters
·
Dec 29, 2025

TRANSCENTA-B (06628) Enters Strategic Collaboration and Non-Exclusive Technology License Agreement with EirGenix

Stock News
·
Dec 29, 2025

Transcenta Therapeutics Announces Strategic Collaboration and Non-Exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics

THOMSON REUTERS
·
Dec 29, 2025

Transcenta Holding Ltd - Announces Collaboration and Non-Exclusive Licensing Agreement With Eirgenix Inc.

THOMSON REUTERS
·
Dec 29, 2025

Transcenta - Grants Eirgenix Non-Exclusive License for Its Highly Intensified Continuous Bioprocessing Platform

THOMSON REUTERS
·
Dec 29, 2025

Transcenta Grants EirGenix License for HiCB Biomanufacturing Platform

Reuters
·
Dec 29, 2025

Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 10,000 Shares at HK$2.14 per Share

Stock News
·
Dec 22, 2025

Transcenta Therapeutics Presents Updated Efficacy Data From the Phase I/Ii Transtar102 Trial of Osemitamab Plus Nivolumab and Capox in First-Line G/Gej Cancer at Esmo Asia

THOMSON REUTERS
·
Dec 05, 2025

TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia

Stock News
·
Dec 05, 2025

Transcenta (Stock Code: 6628) Releases Updated Efficacy Data for Osemitamab Combination in First-Line G/GEJ Cancer

Bulletin Express
·
Dec 05, 2025

Transcenta Reports Promising Phase I/II Trial Results for Osemitamab in G/GEJ Cancer

Reuters
·
Dec 05, 2025

Transcenta (06628) Releases November 2025 Monthly Return on Share Capital and Incentive Schemes

Bulletin Express
·
Dec 04, 2025

Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 20,000 Shares at HK$2.5 Each

Stock News
·
Nov 25, 2025

TRANSCENTA-B (06628) Grants 200,000 Award Shares and 800,000 Share Options

Stock News
·
Nov 20, 2025